ProMIS Neurosciences Issues Letter to Shareholders
08 janv. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...
ProMIS Neurosciences, Inc. Announces Leadership Transition
03 janv. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Announces Publication on Novel Target for ALS
20 déc. 2023 07h00 HE
|
ProMIS Neurosciences Inc.
Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar...
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
20 nov. 2023 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
14 nov. 2023 16h30 HE
|
ProMIS Neurosciences Inc.
Raised $20.4 million in PIPE gross proceeds to support continued development of Company’s PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases ...
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
08 sept. 2023 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the...
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 12h18 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
21 août 2023 16h12 HE
|
ProMIS Neurosciences Inc.
At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS...
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
14 août 2023 17h33 HE
|
ProMIS Neurosciences Inc.
Presented compelling preclinical data supporting therapeutic potential of PMN310 to treat Alzheimer’s disease, and the promise of disease prevention with a computationally derived Alzheimer’s disease...
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
17 juil. 2023 07h00 HE
|
ProMIS Neurosciences Inc.
New findings highlight that PMN310 was able to target toxic amyloid-beta oligomers more selectively than other amyloid-beta-directed antibodies which were generated using synthetic oligomersRationally...